Back to discover
Disease

Injection Site Reaction

Late-stage therapeutic developmentEmerging research
2
Publications
5
Clinical trials
1
Related conditions
2
Related proteins
2025
Latest publication
Current focus
Antibodies biologyTherapeutic developmentInflammation & immunity
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer.

Research2025-02-01The New England journal of medicine

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

Research2021-08-02Journal of clinical oncology : official journal of the American Society of Clinical Oncology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

2 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
5
All trials
0
Active
4
Late-stage
4
Completed

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20212025
Most influential

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 499 cites

Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer.

The New England journal of medicine · 2025 · 78 cites
Recent publications

Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer.

The New England journal of medicine · 2025 · 78 cites

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 499 cites
Major themes5
  • Antibodies, Bispecific1
  • Antineoplastic Agents, Immunological1
  • Neoplasms1
  • Neuregulin-11
  • Oncogene Proteins, Fusion1
Leading journals2
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
  • The New England journal of medicine1
Leading researchers8
  • Goto K2
  • Kim DW2
  • Adeyemi S1
  • Bauml JM1
  • Bekaii-Saab T1
  • Calvo E1
  • Cho BC1
  • Cleary JM1
Affiliations (unnormalised)6
  • National Cancer Center Hospital East2
  • Princess Margaret Cancer Centre2
  • Samsung Medical Center2
  • Yonsei Cancer Center2
  • Abramson Cancer Center1
  • Asan Medical Center1

Disease biology

2 matches

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Adverse reactions that occur initially at the site of injection or infusion. Milder type is confined to a local allergic flare reaction. A more severe reaction is caused by extravasation of VESICANTS from the blood vessel at the site of injection and can cause damage to the surrounding tissue. In tumor flare reaction symptoms involve well beyond the injection site such as an increase in the tumor size and tumor markers levels, bone pain, and HYPERCALCEMIA.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.